Autopsy and Case Reports
https://autopsyandcasereports.org/article/doi/10.4322/acr.2020.230
Autopsy and Case Reports
Short Communication

Bellini duct carcinoma

Gil Falcão; Anuraj Quiran Parmanande; Catarina Araújo; João Vasco Barreira

Downloads: 1
Views: 66

Abstract

ABSTRACT: The modern era has brought an appreciation that renal cell carcinoma (RCC) includes diverse subtypes derived from the various parts of the nephron, each with its distinctive genetic basis and tumor biology. Carcinoma of the collecting ducts of Bellini (CDC) is a rare subtype of RCC, with a predictably poor prognosis. This rare subtype represents less than 1% of all kidney carcinomas. It derives from presumably numerous chromosomal losses. It is of chief importance to differentiate CDC from other types of renal cell cancer. Typically, it is characterized by a firm, centrally located tumor with infiltrative borders. Regarding the histopathologic characteristics, we can find complex, highly infiltrative cords with inflamed (desmoplastic) stroma, with high-grade nuclei and mitoses. Most reported cases of CDC had been high grade, advanced stage, and unresponsive to conventional therapies. This rare form of disease highlights the importance of multidisciplinary teams in the management of cancer patients.

Keywords

Kidney Neoplasms, Carcinoma, Renal Cell, Kidney Tubules, Collecting

References

1 Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215(10):2477-9. http://dx.doi.org/10.1084/jem.20181617. PMid:30217855.

2 Fleming S, Lewi HJ. Collecting duct carcinoma of the kidney. Histopathology. 1986;10(11):1131-41. http://dx.doi.org/10.1111/j.1365-2559.1986.tb02553.x. PMid:3542784.

3 Tokuda N, Naito S, Matsuzaki O, Nagashima Y, Ozono S, Igarashi T. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol. 2006;176(1):40-3. http://dx.doi.org/10.1016/S0022-5347(06)00502-7. PMid:16753362.

4 Mishra AK, Manikandan R, Dorairajan LN, Mittal JK, Rekha JS. Bellini duct carcinoma: a rare entity. J Clin Diagn Res. 2016;10(10):PD01-02. http://dx.doi.org/10.7860/JCDR/2016/21335.8613. PMid:27891395.

5 Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376-81. http://dx.doi.org/10.1200/JCO.2002.11.123. PMid:11981011.

6 Dason S, Allard C, Sheridan-Jonah A, et al. Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol. 2013;20(3):e223-32. http://dx.doi.org/10.3747/co.20.1230. PMid:23737692.

7 Ahrens M, Scheich S, Hartmann A, Bergmann L. Non-clear cell renal cell carcinoma: pathology and treatment options. Oncol Res Treat. 2019;42(3):128-35. http://dx.doi.org/10.1159/000495366. PMid:30799404.

8 Albadine R, Schultz L, Illei P, et al. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol. 2010;34(7):965-9. http://dx.doi.org/10.1097/PAS.0b013e3181dc5e8a. PMid:20463571.
 


Submitted date:
07/10/2020

Accepted date:
08/20/2020

Publication date:
12/08/2020

5fcfc1900e882534054ac229 autopsy Articles
Links & Downloads

Autops Case Rep

Share this page
Page Sections